univers coverag
calendar event
medacorp event ada floor tour nurs view technolog evolut
progress toward artifici pancrea orlando
medic meet america health insur plan feder clinic immunolog
societi intern societi stem cell research societi vascular surgeri
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
assum coverag well-posit execut pt
dcf analysi revenu multipl dr tgr
bottom line assum coverag zai lab zlab outperform op rate
price target pt zai lab china-bas global biopharmaceut compani target area unmet
medic need china global market in-licens intern discoveri effort
oncolog infecti diseas autoimmun diseas view zlab well-posit benefit
china rapidli grow emerg bio-pharma market strong manag team
extens experi in-depth knowledg evolv drug develop commerci
landscap china zlab multipl shot goal broad pipelin asset in-licens
oncolog oncolog omadacyclin infecti diseas addit
zlab earli stage in-hous effort focus immunotherapi target
approach oncolog repres potenti long-term sourc upsid investor
mid-stag trial readout liver cancer mild-moder atop dermat among catalyst watch
mileston catalyst includ
upbeat visit management meet leav us bullish pt
bottom line monday host site visit chanc
catch presid ceo bob palmisano cfo svp lanc berri svp juli dewey
presid kevin cordel presid lower extrem patrick fisher meet
posit left site visit increas confid upward bia estim
head print -- -not recent augment inject fda approv -- -and
achiev above-consensu low-teen revenue growth project balanc
sheet overhang remov augment inject approv hand sens lower
extrem turnaround materi stock set-up risk-reward look increasingli compel us
reiter op rate
specif meet highlight four main posit us
pt increas
posit rytari settlement like extend franchis least
bottom line morn amneal announc reach settlement
first-to-fil ftf teva rytari amneal grant teva licens begin sell gener
rytari begin juli past month manag appear
optimist rytari franchis number reason may suggest
manag becom confid ip posit patent litig case
teva believ still risk patent would hold inde
conserv assum gener entri expir patent expir may
patent litig remain on-going two abbrevi new drug applic anda
filer sandoz zydu settlement see rytari franchis safe
intact expect complet surpris given manag recent
posit commentari see much upsid stock today expect investor
focu remain manag abil launch new product meet guidanc
exchang note provid near-term debt relief
bottom line announc success exchang note provid
near-term debt relief also expect exchang note pro rata basi
condit exchang met announc line tender propos announc
earn deadlin extend reach condit offer exchang
remov near-term matur default risk expens increas interest tender offer would
replac unsecur note second lien reduc second lien capac
mm avail first lien highlight anticip mm liabil
relat conting valuat right cvr liabil opportun use third lien
road believ post exchang next area leverag address term loan
berkshir name ceo healthcar co
bottom line morn amazon jpmorgan berkshir hathaway jointli announc
appoint dr atul gawand ceo new independ healthcar compani
focus employe healthcar link releas dr atul well known surgeon practic
brigham women hospit professor harvard medic school found execut
director ariadn lab health system innov center author sever new york
time bestsel relat scienc healthcar new compani headquart
boston back three compani seemingli great deal freedom
explor incub new care model berkshir first announc partnership
januari seek lower cost better care employe follow health
transform allianc form consortium larg compani
view allianc earli stage take year develop solut potenti
impact exist player like pbm insur provid
bottom line atul gawand name ceo healthcar compani creat
brk dr gawand renown surgeon research writer new compani
oper independ non-profit entiti headquart boston choic
suggest coalit look drug valu chain isol broadli
overal healthcar system across payor provid care deliveri joint entiti begin
approx mm insur live across three employ though meaning portion like
solid ground back clinic pt
 methodolog dcf discount rate termin growth rate
bottom line sinc announc fda lift clinic hold duchenn
muscular dystrophi dmd june link stock experienc boost coincident time
posit read-through sarepta op day june link stock come
recent high follow two event believ present anoth buy opportun
updat model reflect valid compani microdystrophin gene therapi
approach provid data clinic hold lift rais po
assum assum receiv prioriti review voucher prv sell
reiter outperform rais pt
 senior retail clinic kc deal look
pilot humana show clinic strategi
deal ink verscend/verita per share
micro-dystrophin data rais bar dmd wave other
next import catalyst alder six month data ph pivot trial
chronic migrain due second quarter
data present american headach societi
trial expect provid extend durat repeat dose safeti efficaci
month
data expect includ bla eptinezumab need
consist earlier announc data free increas new
advers event increas neutral antibodi
june end post-op pain tka breast augment ph iib
data import discuss note provid pk/
pd data two addit surgic model requir part submiss packag
posit tka studi go long way support commerci effort
pain orthoped surgeri tka
posit breast augment studi provid initi proof concept nerv block
believ stock fulli reflect peak potenti given
potenti best-in-class profil non-opioid altern post-op pain manag
estim revenu post-op indic
see less downsid current level studi posit get mix
result
recent pull-back stock
even tka studi work necessari approv heron still
option conduct anoth larger studi better power prior
launch
nerv block rel smaller opportun compar instal
decemb akao report posit top-lin data two phase studi epic
expect support registr expect primari driver
commerci adopt
epic recruit patient suspect complic urinari tract infect cuti
demonstr plazomicin statist non-inferior meropenem fda primari
endpoint statist superior three key efficaci measur includ ema
primari outcom test cure
see nich role plazo treatment-refractori cuti expect drug
primari clinic util carbapenem-resist enterobacteriacea support
compel data studi albeit small sampl show
reduct death/seri complic mortal respect rel
activ control
continu project peak sale plazomicin ww us sale
row royalti us sale come base upon trajectori
agn avycaz accord medacorp kol gener major sale
off-label use infect
pr medicaid manag care contract triple- first medic
incumb expect announc late june earli juli
within coverag incumb market share total
incumb triple- first medic
market share respect enrol popul elig
request propos rfp receiv respons includ respons
incumb op within coverag
gener premium revenu estim oper loss
puerto rico lower averag pmpm
new contract anticip go-liv octob dictat
puerto rico move oper model mco must provid coverag
across territori one region
upcom catalyst risk adjust data juli earn
tx award octob
announc final patient dravet studi complet dose
may expect report top-lin data trial late june earli juli
dravet syndrom present signific unmet medic need compel clinic
data first two dravet studi render investor physician
patient excit potenti drug
initi phase studi demonstr unpreced level seizur
reduct dravet patient
initi roll nda base result two phase dravet
studi data avail open-label extens suffici
patient exposur support safeti requir file
earlier may report on-going phase iib studi rti elderli
complet dose final patient put trial track top-lin data readout
binari name within coverag univers anticip tremend
volatil around report phase iib top-lin data
believ current impli probability-of-success po studi offer
attract invest opportun investor will accept risk inher
project ww pos-adjust revenu rti /-
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
expect secur fda approv eversens continu glucos
monitor cgm believ nearli total address market
us alon
view eversens appeal broad patient popul encompass
type current declin cgm option due high burden therapi
patient also type reason
alreadi receiv approv eversens eversens xl
europ eversens xl launch uk sweden expect
transit eversens xl europ market
regard us product launch current employe us
commerci team -- readi launch eversens upon fda approv --
compani plan doubl team
fda panel vote unanim favor cgm approv march
believ us approv question
near term secur fda approv eversens time dose claim
like next major catalyst stock
current project us eversens sale
near term secur fda approv eversens time dose claim
like next major catalyst stock
note ph criteria differ nccn guidelin meant trial
result directli compar prior studi
discuss fda on-going primari endpoint determin
told endpoint may similar select ph design
link note
recent pamrevlumab result suggest convent ct scan may accur predict
resect lapc patient
success pamrevlumab neoadjuv set may depend chang resctabl
standard adopt clinic regulatori commerci endpoint
late august omadacyclin antibiot skin pneumonia adcom
key catalyst remain time-frame conven adcom potenti
aug time-frame potenti approv oct time-frame could move
view fda decis panel indic concern
link view panel public forum review posit risk/
benefit profil omadacyclin evidenc last nce antibiot pneumonia
sinc adcom conven
continu view data packag omadacyclin support approv
believ current level street underappreci valu omadacyclin
gain clariti key discuss topic brief document
releas publicli two busi day ahead adcom date
pdufa date expect octob
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
sourc leerink research compani inform factset price prior day
pdufa akao plazomicin complic urinari tract infect bloodstream
fda adcom joint anesthet analges drug product drug safeti
pdufa derm hyperhidrosi excess sweat link impact
medcac panel procedur volum requir hospit heart team
member begin maintain transcathet aortic valv replac
medcac panel t-cell therapi
pdufa teva fremanezumab cgrp migrain
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
feder clinic immunolog societi
intern societi stem cell research
societi vascular surgeri
societi nuclear medicin molecular imag
multi-national associ support cancer intern societi
american orthopaed societi sport medicin
american societi virolog
american societi healthcar engin
societi studi ingest behavior
intern societi thrombosi haemostasi
breast surgeri bodi contour symposium
american societi retina specialist
go live az
model model recent updat pleas contact
leerink repres wish review
 highlight kol panel lung cancer io cell
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
-- flash aducanumab phase trial expand variabl endpt requir
 growth margin management stabil still lack pipelin catalyst market
 ctad medacorp call aducanumab abeta hypothesi
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
celg anoth bet car-t probabl probabl sensibl even
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
biopharma viii partnership acquisit biopharma new top list
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 add cscc respons diseas boost /sni partnership
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
deal capac
moat vs
 insight april nyc hc servic day convict
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
 initi could adenosin inhibit unlock wave i/o
outperform
 come-back stori make survey support opu market
share assumpt outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
